Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
Synopsis: Meptazinol1 is a new opioid-type analgesic with mixed agonist/antagonist properties. It may be given orally, intravenously or intramuscularly. In studies in patients with moderate to severe pain of various aetiologies, usually following surgery or in obstetrics, the characteristics of analgesia with meptazinol were comparable to those seen with equianalgesic doses of pentazocine, pethidine or a combination of dextropropoxyphene and paracetamol. Preoperative use and use as a component of anaesthesia require further investigation before conclusions may be drawn on its effectiveness in these areas. Onset of action, recorded in a few studies, was faster than that with the other analgesics but duration was shorter than that of morphine, buprenorphine and pentazocine. Only a small number of patients with chronic pain have received long term therapy with meptazinol; in such patients there was no need for increased doses as treatment progressed.
Respiratory depression has only been observed in patients receiving meptazinol as a premedication or while undergoing anaesthesia. Similarly any haemodynamic changes have been limited to preoperative patients or patients undergoing anaesthesia. Like other agonist/antagonist analgesic drugs, the abuse potential of meptazinol seems relatively low, but only wider clinical use for longer periods can establish this with certainty. The most commonly reported side effects have been gastrointestinal in nature, and although the incidence of central nervous system side effects has been relatively low, drowsiness and dizziness have caused occasional problems. Thus, meptazinol is a relatively potent but safe addition to the analgesics available for treatment of the patient with moderate to severe pain.
Pharmacodynamic Studies: The opioid agonist activity of meptazinol has been demonstrated in standard animal tests, with a profile of activity characteristic of agonist/ antagonist analgesic compounds. The analgesic action is believed in part to be due to reaction of the drug with opioid receptors, and partly due to an effect on central cholinergic transmission. In analgesic potency assays in animals, meptazinol was estimated to be 2 to 5 times less potent than morphine and less potent than, or equipotent to, pentazocine. Studies in healthy subjects reported meptazinol 200mg to be significantly better than placebo but less effective than pentazocine 50mg in providing analgesia from experimentally induced pain. This result contrasts with those seen in patients.
The narcotic antagonist properties of meptazinol have been demonstrated in various animal models, including the appearance of withdrawal symptoms in morphine-dependent monkeys and exacerbation of the ongoing abstinence syndrome in those animals previously withdrawn for 12 to 14 hours.
Although animal studies revealed an antiarrhythmic effect for meptazinol, no clinically relevant haemodynamic changes have been recorded in healthy subjects or in patients receiving meptazinol for pain of various origins. During anaesthesia, however, meptazinol has resulted in significant alterations of blood pressure, cardiac output, mean arterial pressure, heart rate and rate/pressure product in some patients. Improved ventricular performance has also been reported in some patients.
The respiratory depressant activity of meptazinol has been looked at in healthy volunteers, pre- and postoperative patients, obstetric patients and neonates, and patients undergoing anaesthesia. Significant decreases in respiratory rate were seen only in those given premedication and in patients undergoing anaesthetic procedures.
Animal and human studies suggest that the abuse potential of meptazinol is relatively low. Withdrawal of meptazinol following long term administration in monkeys resulted in minimal abstinence signs. Injection of nalorphine in these animals produced very slight signs, while naloxone injection resulted in slightly more intense signs of withdrawal. Opioid-dependent patients on a methadone withdrawal programme did not suffer any typical withdrawal symptoms following administration cf meptazinol.
Pharmacokinetic Studies: Only limited data are available on the pharmacokinetics of meptazinol in man. Oral administration in healthy subjects resulted in rapid absorption, with peak plasma concentrations being reached within 0.5 to 2 hours. However, as with other phenolic analgesics, bioavailability was low (8.69%) due to an extensive first-pass conjugation. No consistent accumulation was encountered following multiple dosing. Intramuscular administration produced peak plasma levels within 30 minutes, with 99% of steady-state concentrations being achieved before the third dose. Similarly, rectal administration resulted in peak levels which were considerably higher than after oral administration, within 30 minutes of dosing.
Animal studies have demonstrated high concentrations of meptazinol in the lung, spleen, liver and kidneys with some penetration into the brain, especially after intravenous administration. Values for apparent volume of distribution averaged 4.99 L/kg, which is similar to that for pethidine. Neonatal/maternal plasma concentration ratios have ranged from 0.57 to 0.96. A relatively low level of protein binding (27.1%) compared with butorphanol (80%) and buprenorphine (96%) was reported in young healthy subjects. Meptazinol is thought to be extensively metabolised with less than 5% of unchanged drug being recovered in the urine, the major metabolite being the glucuronide conjugate of the parent drug. Excretion was fairly rapid and took place chiefly via the urine with over 50% of the dose predominantly in the conjugated form being recovered in the first 9 hours. Elimination half-lives averaged 2 hours or less and plasma clearance values averaged 2.2 L/min. Age seemed to have little influence on the kinetics of meptazinol because, although the elimination half-lives in the elderly were extended (3.39h after a single dose and 4.97h after multiple doses), peak plasma concentrations after single and multiple doses were similar.
Therapeutic Trials: A number of open studies have reported meptazinol to be an effective analgesic when given orally (100 to 700mg daily), intravenously (100 to 200mg daily) or intramuscularly (100mg daily) in patients with moderate to severe pain from a variety of causes. Meptazinol given orally has proved to be significantly more effective than placebo in providing relief of pain in a limited number of patients with moderate to severe pain of different origin.
Meptazinol, usually given orally or intramuscularly, has been compared with morphine, pentazocine, pethidine (meperidine), buprenorphine, papaveretum, paracetamol (acetaminophen), a combination of dextropropoxyphene and paracetamol, and one of hyoscine-N-butylbromide and dipyrone. Generally, similar analgesic effects were evident for meptazinol and pethidine, pentazocine or the combination of dextropropoxyphene and paracetamol; in one or two studies a greater degree of analgesia was produced by meptazinol than pethidine or pentazocine. The single studies involving comparisons of meptazinol with papaveretum and paracetamol found no significant difference in the analgesia produced by the 2 drugs. Only buprenorphine has proven significantly more effective than meptazinol in provision of analgesia. The results of studies with morphine would suggest that meptazinol may be as effective in maintaining analgesia. Duration of effect of meptazinol was less than that of morphine, buprenorphine and, in 1 study, pentazocine, but equal to that of pethidine, and a combination of hyoscine butylbromide and dipyrone. However, onset of action (where recorded) showed meptazinol to be significantly faster than morphine, pentazocine and the hyoscine-N-butylbromide/dipyrone combination.
Meptazinol given intramuscularly in doses of 75 to 150mg has proved to be an effective obstetric analgesic and is without serious adverse effects on the neonate. The use of meptazinol in anaesthesia has not been adequately investigated. One trial reported an adequate response when combined with hyoscine as a premedication, whilst the other found an unacceptably high level of side effects when meptazinol was included in the anaesthetic technique.
Side Effects: The most common side effects associated with meptazinol administration are the gastrointestinal effects such as nausea and vomiting. Drowsiness and dizziness may also be a frequent problem, but the incidence of other central nervous system side effects has been comparatively low. Although a slightly higher incidence of adverse effects was seen during obstetric use, the condition of the majority of newborn babies was unaffected by the drug. Significant decreases in respiratory rate were seen only preoperatively and in anaesthetised patients, while no serious haemodynamic changes were reported following meptazinol administration.
Dosage and Administration: Meptazinol is available for oral and parenteral use. Recommended oral doses for adults are 200mg 3- to 6-hourly as required, with a usual dose of 200mg 4-hourly. Intramuscular doses of 75 to 100mg may be repeated every 2 to 4 hours if required. Slightly higher intramuscular doses (100 to 150mg) are used in obstetrics, calculated on a weight basis of approximately 2 mg/kg. Slow intravenous injections of 50 to 100mg may be repeated 2- to 4-hourly as required. The possibility of withdrawal symptoms precipitated by meptazinol should be looked for in patients who have previously taken opioids for long periods.
- Bill, D.J.; Hartley, J.E.; Stephens, R.J. and Thompson, A.M.: The antinociceptive activity of meptazinol depends on both opiate and cholinergic mechanisms. British Journal of Pharmacology 79: 191–199 (1983).
- Broadley, J.; Wilson, T. and Robson, F.: The use of meptazinol as premedication for surgical patients. Journal of International Medical Research 10: 225–228 (1982).
- Brunck, S.F. and Delle, M.S.: Morphine metabolism in man. Clinical Pharmacology and Therapeutics 16: 51–57 (1974).
- Budd, K.; Brown, P.M. and Robson, P.J.: The treatment of chronic pain by the use of meptazinol administered into the epidural space. Postgraduate Medical Journal 59: 68–71 (1983).
- Caldwell, J.; Wakile, L.A.; Notarianni, L.J.; Smith, R.L.; Correy, G.J. et al.: Maternal and neonatal disposition of pethidine in childbirth — a study using quantitative gas chromatographymass spectrometry. Life Sciences 22: 589–596 (1978).
- Camu, F. and Rucquoi, M.: Cardiac and circulatory effects of high-dose meptazinol in anaesthetized patients. Postgraduate Medical Journal 59 (Suppl. 1): 60–63 (1983).
- Caruso, F.S.; Pircio, A.W.; Maddisso, H.; Smyth, R.D. and Potcher, I.J.: Butorphanol. Pharmacol. Biochem. Prop. Drug Subst. 2: 19–57 (1979).
- Church, J.J.: Continuous infusion of meptazinol and pethidine in the relief of post-operative pain. Postgraduate Medical Journal 59: 41–46 (1983).
- Cohen, D.G.; Major, E; Jothilingham, S.; Clark, G. and Coutinho, P.: Meptazinol in the treatment of severe post-operative pain. A comparison with morphine. Postgraduate Medical Journal 59: 35–40 (1983).
- Collier, H.O.J.; Dinneen, L.C.; Johnson, C.A. and Schneider, C.: The abdominal constriction response and its suppression by analgesic drugs in the mouse. British Journal of Pharmacology 32: 295–310 (1968).
- Collier, H.O.; Hammond, A.R.; Horwood-Barrett, S. and Schneider, C.: Rapid induction by acetylcholine, bradykinin and potassium of a nociceptive response in mice and its selective antagonism by aspirin. Nature 204: 1316–1318 (1964).
- Cooper, S.A.: Double-blind comparison of zomepirac sodium, propoxyphene/acetaminophen and placebo in the treatment of oral surgical pain. Current Therapeutic Research 28: 630–638 (1980).
- Copeland, S.A.: Preliminary evaluation of the use of meptazinol in trauma. Postgraduate Medical Journal 59: 64–66 (1983).
- Coutinho, A.: Clinical evaluation of a new opium-antagonist analgesic — meptazinol. Journal of British Urology 6: 156–162 (1980).
- Cowlrick, I.S. and Shepperson, N.B.: The effects of a new opioid analgesic, meptazinol, on the respiration of the conscious rat. British Journal of Pharmacology 85: 206 (1985).
- Davies, G.; Sinclair, A.J.; Warrington, S.J.; Franklin, R.; Frost, T. et al.: Pharmacokinetics of meptazinol in man following repeated intramuscular administration. European Journal of Clinical Pharmacology 23: 535–538 (1982).
- de Rosayro, M.; Healy, T.E.J. and Morris, G.K.: Meptazinol and morphine compared: A study using systolic time intervals. Pharmatherapeutica 2: 523–527 (1981).
- Dowell, P.S.; Pierce, D.M.; Franklin, R.A.; Robson, P.J. and Jackson, M.B.A.: Routes of meptazinol conjugation in the neonate. British Journal of Clinical Pharmacology 14: 748–750 (1982).
- Ehrnebo, M.; Boréus, L.O. and Lönroth, U.: Bioavailability and first pass metabolism of oral pentazocine in man. Clinical Pharmacology and Therapeutics 22: 883–892 (1978).
- Errick, J.K. and Heel, R.C.: Nalbuphine: A preliminary review of its pharmacological properties and therapeutic efficacy. Drugs 26: 191–211 (1983).
- Evans, M.; Robson, P.J.; Chadd, M.A.; Evans, C.M. and Fry, D.M.: Administration of meptazinol to opiate-dependent patients. Postgraduate Medical Journal 59: 78–84 (1983).
- Fagbemi, O.; Kane, K.A.; Lepran, I.; Parratt, J.R. and Szekeres, L.: Antiarrhythmic actions of meptazinol, a partial agonist at opiate receptors, in acute myocardial ischaemia. British Journal of Pharmacology 78: 455–460 (1983).
- Flavell-Matts, S.G. and Ward, P.J.: A double blind comparison of meptazinol versus pentazocine in chronic rheumatoid and osteoarthritis. British Journal of Clinical Practice 34: 286–289 (1980).
- Franklin, R.A.: The influence of gastric emptying on plasma concentrations of the analgesic meptazinol. British Journal of Pharmacology 59: 565–569 (1977).
- Franklin, R.A. and Aldridge, A.: Pharmacokinetics and metabolism of the new analgesic meptazinol in rats and patas monkeys. Xenobiotica 6: 499–508 (1976).
- Franklin, R.A.; Aldridge, A. and de B. White, C.: Preliminary metabolic studies on the new analgesic meptazinol. British Journal of Clinical Pharmacology 2: 472–473 (1975).
- Franklin, R.A.; Aldridge, A. and de B. White, C.: Studies on the metabolism of meptazinol, a new analgesic drug. British Journal of Clinical Pharmacology 3: 497–502 (1976).
- Franklin, R.A.; Frost, T.; Robson, P.J. and Jackson, M.B.A.: Preliminary studies on the disposition of meptazinol in the neonate. British Journal of Clinical Pharmacology 12: 88–90 (1981).
- Franklin, R.A.; Southgate, P.J. and Coleman, A.J.: Studies on the absorption and disposition of meptazinol following rectal administration. British Journal of Clinical Pharmacology 4: 163–167 (1977).
- Gabka, J. and Price, R.K.J.: Tooth pulp stimulation: A method of determining the analgesic efficacy of meptazinol in man. British Journal of Clinical Pharmacology 14: 104–106 (1982).
- Gepts, E.; Sonck, W.; Rucquoi, M.; Vercruysse, A. and Camu, F.: Disposition of meptazinol (mep), an agonist antagonist analgesic, in man. IUPHAR 9th International Congress of Pharmacology, Abstract No. 1766P, London (1984).
- Gibbs, J.M. and Johnson, H.D.: A trial of meptazinol for the relief of pain after abdominal surgery. Anaesthesia and Intensive Care 8: 441–444 (1980).
- Goldstuck, N.D. and Ward, P.J.: Treatment of pain following IUD insertion with meptazinol — a new centrally acting analgesic. Contraceptive Delivery Systems 4: 33–37 (1983).
- Goode, P.G.: An implanted reservoir of morphine solution for rapid induction of physical dependence in rats. British Journal of Pharmacology 41: 558–566 (1971).
- Goode, P.G.; Rhodes, K.F. and Waterfall, J.F.: The analgesic and respiratory effects of meptazinol, morphine, and pentazocine in the rat. Journal of Pharmacy and Pharmacology 31: 793–795 (1979).
- Goode, P.G. and White, A.C.: Some properties of Wy 22811, a new analgesic compound. British Journal of Pharmacology 43: 462–463P (1971).
- Green, D.: Current concepts concerning the mode of action of meptazinol as an analgesic. Postgraduate Medical Journal 59 (Suppl. 1): 9–12 (1983).
- Griffiths, M.J. and Thomas, T.A.: A comparison of the analgesic effects of meptazinol and pentazocine following removal of impacted third molars. British Dental Journal 158: 19–21 (1985).
- Hardy, P.A.J.: Meptazinol and respiratory depression. Lancet 2: 576 (1983).
- Harmer, M.; Slatterly, P.J.; Rosen, M. and Vickers, M.D.: Intramuscular on demand analgesia: Double blind controlled trial of pethidine, buprenorphine, morphine and meptazinol. British Medical Journal 286: 680–682 (1983).
- Hardy, P.A.J.: Meptazinol and Respiratory Depression. Lancet 2: 576 (1983).
- Hedges, A.; Turner, P. and Wadsworth, J.: A double-blind comparison of meptazinol with pethidine in post-operative pain. British Journal of Anaesthesia 52: 295–298 (1980).
- Hedges, A.; Rose, J.; Leighton, M. and Turner, P.: A double-blind comparison of meptazinol with placebo in post-operative pain. Journal of Clinical Pharmacology 17: 125–127 (1977).
- Heel, R.C.; Brogden, R.N.; Speight, T.M. and Avery, G.S.: Buprenorphine: A review of its pharmacological properties and therapeutic efficacy. Drugs 17: 81–110 (1979).
- Huddy, N.C. and Duncan, J.J.: Precipitation between meptazinol and thiopentone. Anaesthesia 38: 601–602 (1983).
- Jackson, M.B.A.: Obstetric Analgesia. Proceedings of a Symposium on Current Advances on the Control of Acute and Chronic Pain. John Radcliffe Hospital, Oxford (1983).
- Jackson, M.B.A. and Robson, P.J.: Preliminary experience of the use of meptazinol as an obstetric analgesic. British Journal of Obstetrics and Gynaecology 87: 296–301 (1980).
- Jackson, M.B.A. and Robson, P.J.: Preliminary clinical and pharmacokinetic experiences in the newborn when meptazinol is compared with pethidine as an obstetric analgesic. Postgraduate Medical Journal 59 (Suppl. 1): 47–51 (1983).
- Jordan, C.; Lehare, J.R.; Robson, P.J. and Jones, J.G.: A comparison of the respiratory effects of meptazinol pentazocine and morphine. British Journal of Anaesthesia 51: 497–502 (1979).
- Kingston, H.G.G.: Meptazinol used after open heart surgery. Postgraduate Medical Journal 59: 54–56 (1983).
- Keen, M.R. and Owen, A.: Comparison of the effects of single i.m. dose of meptazinol (100mg), methadone (20 and 40mg) and placebo in opiate addicts. Postgraduate Medical Journal 61 (Suppl. 2): 27–28 (1985).
- Malis, J. and Gluckman, M.: in Braude et al. (Eds) Narcotic Antagonists (Raven Press, New York 1974).
- Mather, L.E.; Tucker, G.T.; Pflug, A.E.; Lindop, M.J. and Wilkerson, C.: Meperidine kinetics in man. Clinical Pharmacology and Therapeutics 17: 21–30 (1974).
- Moyes, D.G.; Miller, M.T. and Aldridge, N.J.: A comparison between meptazinol and omnopon in the relief of post-operative pain. South African Medical Journal 55: 865–866 (1979).
- Murray, W.J.: Evaluation of aspirin in treatment of headache. Clinical Pharmacology and Therapeutics 5: 21–25 (1964).
- Nel, C.P.; Bloch, B. and Rush, J.M.: A comparison of meptazinol and pethidine for pain relief during the first stage of labour. South African Medical Journal 59: 908–910 (1981).
- Nicholas, A.D.G.: Routine use of meptazinol in labour. Postgraduate Medical Journal 59: 52 (1983).
- Nicholas, A.D.G. and Robson, P.J.: Double-blind comparison of meptazinol and pethidine in labour. British Journal of Obstetrics and Gynaecology 89: 318–322 (1982).
- Norbury, H.M.; Franklin, R.A. and Graham, D.F.: Pharmacokinetics of the new analgesic, meptazinol, after oral and intravenous administration to volunteers. European Journal of Clinical Pharmacology 25: 77–80 (1983).
- Norbury, H.M.; Franklin, R.A.; Graham, D.F. and Sinha, B.: Pharmacokinetics of meptazinol after single and multiple oral administration to elderly patients. European Journal of Clinical Pharmacology 27: 223–226 (1984).
- O’Callaghan, J.P. and Holtzmann, S.G.: Quantification of the analgesic activity of narcotic antagonists by a modified hot plate procedure. Journal of Pharmacology and Experimental Therapeutics 192: 497–505 (1975).
- Oosterlinck, W. and DeSy, W.: Preliminary clinical experience with meptazinol, a new analgesic. Current Medical Research and Opinion 3: 187–191 (1975).
- Oosterlinck, W. and DeSy, W.: A double-blind comparison between meptazinol (Wy 22811 ) and ‘Buscopan’ Compositum in renal colic. Current Medical Research and Opinion 3: 716–718 (1976).
- Parker, C.E. and Langrick, A.F.: A double-blind comparison of meptazinol and placebo in patients with acute and chronic pain presenting to the general practitioner. Journal of International Medical Research 10: 408–413 (1982).
- Paymaster, N.J.: Clinical evaluation of meptazinol a new analgesic in post-operative pain. British Journal of Anaesthesia 48: 599–605 (1976a).
- Paymaster, N.J.: Clinical assessment of oral meptazinol in postoperative pain. Acta Anaesthesiologica Belgica 27: 159–170 (1976b).
- Paymaster, N.J.: Analgesia after an operation: A controlled comparison of meptazinol, pentazocine and pethidine. British Journal of Anaesthesia 49: 1139–1146 (1977).
- Paymaster, N.J.: Intramuscular meptazinol analgesia after surgery: A study of the dose-response effect and a controlled comparison with pentazocine and pethidine. Postgraduate Medical Journal 59 (Suppl. I): 25–31 (1983).
- Pearce, V. and Robson, P.J.: Double-blind crossover trial of oral meptazinol, pentazocine and placebo in the treatment of pain in the elderly. Postgraduate Medical Journal 56: 474–477 (1980).
- Pereira, E.S.: Clinical assessment of intramuscular meptazinol in post-operative pain. Revista Brasileira de Clinica e Terapêutica 9: 408–413 (1980).
- Pert, C.B. and Snyder, S.H.: Opiate receptor binding of agonists and antagonists affected differentially by sodium. Molecular Pharmacology 10: 868–879 (1974).
- Price, R.K.J. and Latham, A.N.: Long-term assessment of the efficacy and safety of oral meptazinol (200mg) in general practice. Current Therapeutic Research 31: 807–812 (1982a).
- Price, R.K.J. and Latham, A.N.: Double-blind comparison of meptazinol (200mg) and dextropropoxyphene/paracetamol in a multicentre, general practice setting. Current Medical Research and Opinion 8: 54–60 (1982b).
- Price, R.K.J. and Latham, A.N.: Pain type and sex dependent responses to a placebo controlled multicentre analgesic trial. Clinical Trials Journal 19: 107–115 (1982c).
- Rashid, S. and Waterfall, J.F.: Cardiovascular actions of meptazinol in comparison with pentazocine and morphine. General Pharmacology 10: 459–464 (1979).
- Rashid, S.: Effect of antidysrhythmic and analgesic drugs on haemodynamics and fibrillatory threshold. Journal of the Pakistan Medical Association 31: 141–145 (1981).
- Robson, P.J.: Clinical review of parenteral meptazinol. Postgraduate Medical Journal 59 (Suppl. I): 85–92 (1983).
- Rosseel, M.T.; Bogaert M.G.; Verschraegen, R. and Staquet, M.: Plasma concentrations of meptazinol (Wy 22811) after different routes of administration in man. Pharmatherapeutica 1: 270–276 (1976).
- Rosseel, M.T.; Bogaert, M.G.; Belpaire, F.M. and Oosterlinck, W.: Meptazinol (Wy 22811), a new analgesic: Preliminary pharmacokinetic data. Current Medical Research and Opinion 3: 181–186 (1975).
- Schindel, L.: The placebo dilemma. European Journal of Clinical Pharmacology 13: 231–235 (1978).
- Slatterly, P.J.; Harmer, M.; Rosen, M. and Vickers, M.: Comparison of the respiratory depressant effects of IV meptazinol and pethidine. British Journal of Anaesthesia 55: 245P (1983).
- Slatterly, P.J.; Harmer, M.; Rosen, M. and Vickers, M.D.: Naloxone reversal of meptazinol induced respiratory depression. Anaesthesia 37: 1163–1166 (1982).
- Slatterly, P.J.; Harmer, M.; Rosen, M. and Vickers, M.D.: Comparison of meptazinol and pethidine given IV on demand in the management of post operative pain. British Journal of Anaesthesia 53: 927–931 (1981).
- Snyder, S.H.: The brain’s own opiates. Chemical and Engineering News (Nov 28): 26–36 (1977).
- Sonecha, T.; Abdel-Hadi, A; Basterman, E.M.M. and Kidner, P.H.: Initial assessment of meptazinol in the treatment of pain in myocardial infarction/unstable angina. Postgraduate Medical Journal 59: 57–59 (1983).
- Speigel, K. and Pasternak, G.W.: Meptazinol: A novel Mu-1 selective opioid analgesic. Journal of Pharmacology and Experimental Therapeutics 288: 414–419 (1984).
- Stacher, G.; Steinringer, H.; Winklehner, S.; Mittelbach, G. and Schneider, C.: Effects of graded oral doses of meptazinol and pentazocine in comparison with placebo on experimentally induced pain in healthy humans. British Journal of Clinical Pharmacology 16: 149–156 (1983).
- Staquet, M.: A double-blind comparison of meptazinol with pentazocine and placebo in cancer pain. Journal of Clinical Pharmacology 18: 76–79 (1978).
- Strahan, K. and Pleuvry, B.J.: Interactions between meptazinol and neuromuscular blocking agents. British Journal of Anaesthesia 56: 1290P (1984).
- Stephens, R.J.: Evidence for a pharmacokinetic interaction between ibuprofen and meptazinol in the mouse. Journal of Pharmacy and Pharmacology 36: 779–781 (1984).
- Stephens, R.J.; Waterfall, J.F. and Franklin, R.A.: A review of the biological properties and metabolic disposition of the new analgesic agent, meptazinol. General Pharmacology 9: 73–78 (1978).
- Teklu, B.; Habte-Michael, A.; Warrell, D.A.; White, N.J. and Wright, D.J.M.: Meptazinol diminishes the Jarisch-Herxheimer reaction of relapsing fever. Lancet 1: 835–839 (1983).
- Tyers, M.B.: A classification of opiate receptors that mediate antinociception in animals. British Journal of Pharmacology 69: 503–512 (1980).
- Verschraegen, R. and Roily, G.: Double blind study of meptazinol versus pentazocine and placebo in post operative pain treatment. Acta Anaesthesiologica Belgica 30: 255–264 (1979).
- Verschraegen, R.; Rosseel, M.T.; Bogaert, M. and Roily, G.: Meptazinol: IM use in post operative pain. Acta Anaesthesiologica Belgica 27 (Suppl.): 123–132 (1976).
- Videman, T.; Heikkilä, J. and Partanen, T.: Double-blind parallel study of meptazinol versus diflunisal in the treatment of lumbago. Current Medical Research and Opinion 9: 246–252 (1984).
- Wade, A.G. and Ward, P.J.: First impressions of the use of meptazinol in general practice. Journal of International Medical Research 9: 74–78 (1981).
- Wade, A.G. and Ward, P.J.: A double-blind comparison of meptazinol versus distalgesic in acute or chronic pain presenting to the general practitioner. Journal of International Medical Research 10: 104–108 (1982b).
- Wade, A.G. and Ward, P.J.: A double-blind comparison of meptazinol versus paracetamol and placebo in acute and chronic painful conditions presenting to the general practitioner. Current Medical Research and Opinion 8: 191–196 (1982a).
- Ward, P.J.: Double-blind comparison of meptazinol versus pentazocine in patients with chronic backache. Current Therapeutic Research 30: 507–514 (1981).
- Warrington, S.J.; Barclay, S.P.; Brown, Z. and Robson, P.J.: Reversibility of the analgesic effect of meptazinol in volunteers. Postgraduate Medical Journal 59(Suppl. I) 13–18 (1983).
- Westcombe, R.E. and Price, R.K.J.: Meptazinol in the casualty department: A comparison against morphine. Current Therapeutic Research 37: 969–979 (1985).
Volume 30, Issue 4 , pp 285-312
- Cover Date
- Print ISSN
- Online ISSN
- Springer International Publishing
- Additional Links
- Industry Sectors